Injection of anti-DEC-205-OVA conjugate in mice was taken up by draining lymph node DCs and stimulated CD8+ T (OT-I) cells 400 times more efficiently compared to OVA alone; this response was further enhanced in vivo (as measured by IL-2, IFN-gamma, CTL, and tumor protection), with the addition of anti-CD40 antibody (a DC maturation stimulus) [176]. The gene discussed is CD40; the disease is neoplasm.